These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 9678784)

  • 1. Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification.
    Tertov VV; Kaplun VV; Sobenin IA; Orekhov AN
    Atherosclerosis; 1998 May; 138(1):183-95. PubMed ID: 9678784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein.
    Tertov VV; Kaplun VV; Sobenin IA; Boytsova EY; Bovin NV; Orekhov AN
    Atherosclerosis; 2001 Nov; 159(1):103-15. PubMed ID: 11689212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization.
    Tertov VV; Sobenin IA; Gabbasov ZA; Popov EG; Jaakkola O; Solakivi T; Nikkari T; Smirnov VN; Orekhov AN
    Lab Invest; 1992 Nov; 67(5):665-75. PubMed ID: 1434544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desialylated low density lipoprotein--naturally occurring modified lipoprotein with atherogenic potency.
    Orekhov AN; Tertov VV; Mukhin DN
    Atherosclerosis; 1991 Feb; 86(2-3):153-61. PubMed ID: 1872910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients.
    Orekhov AN; Tertov VV; Mukhin DN; Mikhailenko IA
    Biochem Biophys Res Commun; 1989 Jul; 162(1):206-11. PubMed ID: 2751649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similarity between naturally occurring modified desialylated, electronegative and aortic low density lipoprotein.
    Tertov VV; Sobenin IA; Orekhov AN
    Free Radic Res; 1996 Oct; 25(4):313-9. PubMed ID: 8889495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atherogenic modification of low-density lipoproteins].
    Sukhorukov VN; Karagodin VP; Orekhov AN
    Biomed Khim; 2016 May; 62(4):391-402. PubMed ID: 27562992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells.
    Sobenin IA; Tertov VV; Koschinsky T; Bünting CE; Slavina ES; Dedov II; Orekhov AN
    Atherosclerosis; 1993 Apr; 100(1):41-54. PubMed ID: 8318062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate composition of circulating multiple-modified low-density lipoprotein.
    Zakiev ER; Sobenin IA; Sukhorukov VN; Myasoedova VA; Ivanova EA; Orekhov AN
    Vasc Health Risk Manag; 2016; 12():379-385. PubMed ID: 27789955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo oxidized low density lipoprotein: degree of lipoprotein oxidation does not correlate with its atherogenic properties.
    Tertov VV; Kaplun VV; Orekhov AN
    Mol Cell Biochem; 1998 Jun; 183(1-2):141-6. PubMed ID: 9655188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions.
    Tertov VV; Bittolo-Bon G; Sobenin IA; Cazzolato G; Orekhov AN; Avogaro P
    Exp Mol Pathol; 1995 Jun; 62(3):166-72. PubMed ID: 8612720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima.
    Tertov VV; Orekhov AN
    Exp Mol Pathol; 1997; 64(3):127-45. PubMed ID: 9439479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation.
    Tabas I; Li Y; Brocia RW; Xu SW; Swenson TL; Williams KJ
    J Biol Chem; 1993 Sep; 268(27):20419-32. PubMed ID: 8376399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro.
    Tertov VV; Sobenin IA; Kaplun VV; Orekhov AN
    Free Radic Res; 1998 Aug; 29(2):165-73. PubMed ID: 9790519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Desialylated low density lipoproteins--atherogenic lipoproteins occurring in blood of patients with coronary atherosclerosis].
    Mukhin DN; Tertov VV; Kacharava AG; Orekhov AN
    Biull Eksp Biol Med; 1990 Aug; 110(8):138-40. PubMed ID: 2291955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic modified LDL in diabetes.
    Sobenin IA; Tertov VV; Orekhov AN
    Diabetes; 1996 Jul; 45 Suppl 3():S35-9. PubMed ID: 8674887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E-deficient mice.
    Maor I; Hayek T; Coleman R; Aviram M
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2995-3005. PubMed ID: 9409286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.
    Millar JS; Anber V; Shepherd J; Packard CJ
    Atherosclerosis; 1999 Aug; 145(2):253-60. PubMed ID: 10488950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis.
    Tertov VV; Orekhov AN; Kacharava AG; Sobenin IA; Perova NV; Smirnov VN
    Exp Mol Pathol; 1990 Jun; 52(3):300-8. PubMed ID: 2369935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple-modified Low-Density Lipoprotein as Atherogenic Factor of Patients' Blood: Development of Therapeutic Approaches to Reduce Blood Atherogenicity.
    Nikiforov NG; Zakiev ER; Elizova NV; Sukhorukov VN; Orekhov AN
    Curr Pharm Des; 2017; 23(6):932-936. PubMed ID: 28120723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.